Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    CA209-714
Previous Study | Return to List | Next Study

Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CheckMate 714)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02823574
Recruitment Status : Completed
First Posted : July 6, 2016
Results First Posted : April 21, 2022
Last Update Posted : April 21, 2022
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb

Brief Summary:
A study in patients with metastatic or recurrent squamous cell cancer of the head and neck to evaluate the effectiveness of Nivolumab plus Ipilumumab vs. Nivolumab alone (CheckMate 714)

Condition or disease Intervention/treatment Phase
Head and Neck Cancer Biological: Nivolumab Biological: Ipilimumab Other: Placebo Phase 2

Expanded Access : An investigational treatment associated with this study has been approved for sale to the public.   More info ...

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 425 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Actual Study Start Date : October 20, 2016
Actual Primary Completion Date : January 23, 2019
Actual Study Completion Date : March 11, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Nivolumab and Ipilimumab
Specified dose on specified days
Biological: Nivolumab
Other Name: Opdivo

Biological: Ipilimumab
Active Comparator: Nivolumab and Ipilimumab-placebo
Specified dose on specified days
Biological: Nivolumab
Other Name: Opdivo

Other: Placebo



Primary Outcome Measures :
  1. Objective Response Rate (ORR) as Determined by Blinded Independent Central Review (BIRC) - Platinum Refractory Subgroup [ Time Frame: Approximately up to 30 months (from FPFV to Data base lock) ]
    ORR is defined as best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized participants for each treatment group.

  2. Duration of Response (DOR) as Determined by Blinded Independent Central Review (BIRC) - Platinum Refractory Subgroup [ Time Frame: Approximately up to 30 months (from FPFV to Data base lock) ]
    The time between the date of first confirmed response to the date of the first documented tumor progression, or death due to any cause, whichever occurs first.

  3. Time to Response (TTR) as Determined by Blinded Independent Central Review (BIRC) - Platinum Refractory Subgroup [ Time Frame: Approximately up to 30 months (from FPFV to Data base lock) ]
    Time to Response (TTR) for participants demonstrating a response (either CR or PR) was defined as the time from the date of randomization to the date of the first confirmed response.


Secondary Outcome Measures :
  1. Objective Response Rate (ORR) as Determined by Blinded Independent Central Review (BIRC) - Platinum Eligible Subgroup [ Time Frame: Approximately up to 30 months (from FPFV to Data base lock) ]
    ORR is defined as best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized participants for each treatment group.

  2. Duration of Response (DOR) as Determined by Blinded Independent Central Review (BIRC) - Platinum Eligible Subgroup [ Time Frame: Approximately up to 30 months (from FPFV to Data base lock) ]
    The time between the date of first confirmed response to the date of the first documented tumor progression, or death due to any cause, whichever occurs first.

  3. Progression Free Survival (PFS) as Determined by Blinded Independent Central Review (BIRC) - Platinum Refractory Subgroup [ Time Frame: Approximately up to 30 months (from FPFV to Data base lock) ]
    the time from randomization to the date of first documented disease progression, or death due to any cause, whichever occurs first.

  4. Progression Free Survival (PFS) as Determined by Blinded Independent Central Review (BIRC) - Platinum Eligible Subgroup [ Time Frame: Approximately up to 30 months (from FPFV to Data base lock) ]
    the time from randomization to the date of first documented disease progression, or death due to any cause, whichever occurs first.

  5. Overall Survival (OS) [ Time Frame: Approximately up to 30 months (from FPFV to Data base lock) ]
    Overall survival was defined as the time from randomization to the date of death from any cause. Participants were censored at the date they were last known to be alive and at the date of randomization if they were randomized but had no follow-up.

  6. Overall Survival (OS) - Platinum Refractory Subgroup [ Time Frame: Approximately up to 30 months (from FPFV to Data base lock) ]
    Overall survival was defined as the time from randomization to the date of death from any cause. Participants were censored at the date they were last known to be alive and at the date of randomization if they were randomized but had no follow-up.

  7. Overall Survival (OS) - Platinum Eligible Subgroup [ Time Frame: Approximately up to 30 months (from FPFV to Data base lock) ]
    Overall survival was defined as the time from randomization to the date of death from any cause. Participants were censored at the date they were last known to be alive and at the date of randomization if they were randomized but had no follow-up.

  8. ORR - Platinum Eligible Subgroup Based on HPV p-16 Status [ Time Frame: Approximately up to 30 months (from FPFV to Data base lock) ]
    ORR is defined as the best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized participants for each treatment group.

  9. ORR - Platinum Eligible Subgroup Based on Tumor Mutation Burden (TMB) Biomarker [ Time Frame: Approximately up to 30 months (from FPFV to Data base lock) ]

    ORR is defined as the best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized participants for each treatment group.

    Tumor Mutational Burden (TMB) refers to the number of nonsynonymous somatic mutations that exist within a tumor's genome as measured by the Foundation One CDx panel at Foundation Medicine. The analysis was done on subjects with baseline tumor mutation burden by a cutoff of 7 mutations/megabase (mut/Mb) and 10 mut/Mb


  10. ORR - Platinum Refractory Subgroup Based on HPV p-16 Status [ Time Frame: Approximately up to 30 months (from FPFV to Data base lock) ]
    ORR is defined as the best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized participants for each treatment group.

  11. ORR - Platinum Refractory Subgroup Based on Tumor Mutation Burden (TMB) Biomarker [ Time Frame: Approximately up to 30 months (from FPFV to Data base lock) ]

    ORR is defined as the best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized participants for each treatment group.

    Tumor Mutational Burden (TMB) refers to the number of nonsynonymous somatic mutations that exist within a tumor's genome as measured by the Foundation One CDx panel at Foundation Medicine. The analysis was done on subjects with baseline tumor mutation burden by a cutoff of 7 mutations/megabase (mut/Mb) and 10 mut/Mb


  12. Duration of Response (DOR) - Platinum Refractory Subgroup Based on HPV p-16 Status [ Time Frame: Approximately up to 30 months (from FPFV to Data base lock) ]
    The time between the date of first confirmed response to the date of the first documented tumor progression, or death due to any cause, whichever occurs first.

  13. Duration of Response (DOR) - Platinum Refractory Subgroup Based on Tumor Mutation Burden (TMB) Status [ Time Frame: Approximately up to 30 months (from FPFV to Data base lock) ]

    The time between the date of first confirmed response to the date of the first documented tumor progression, or death due to any cause, whichever occurs first.

    Tumor Mutational Burden (TMB) refers to the number of nonsynonymous somatic mutations that exist within a tumor's genome as measured by the Foundation One CDx panel at Foundation Medicine. The analysis was done on subjects with baseline tumor mutation burden by a cutoff of 7 mutations/megabase (mut/Mb) and 10 mut/Mb


  14. Progression Free Survival (PFS) - Platinum Refractory Subgroup Based on HPV p-16 Status [ Time Frame: Approximately up to 30 months (from FPFV to Data base lock) ]
    the time from randomization to the date of first documented disease progression, or death due to any cause, whichever occurs first.

  15. Progression Free Survival (PFS) - Platinum Refractory Subgroup Based on Tumor Mutation Burden (TMB) Status [ Time Frame: Approximately up to 30 months (from FPFV to Data base lock) ]

    the time from randomization to the date of first documented disease progression, or death due to any cause, whichever occurs first.

    Tumor Mutational Burden (TMB) refers to the number of nonsynonymous somatic mutations that exist within a tumor's genome as measured by the Foundation One CDx panel at Foundation Medicine. The analysis was done on subjects with baseline tumor mutation burden by a cutoff of 7 mutations/megabase (mut/Mb) and 10 mut/Mb


  16. Overall Survival (OS) - Platinum Refractory Subgroup Based on HPV p-16 Status [ Time Frame: Approximately up to 30 months (from FPFV to Data base lock) ]
    Overall survival was defined as the time from randomization to the date of death from any cause. Participants were censored at the date they were last known to be alive and at the date of randomization if they were randomized but had no follow-up.

  17. Overall Survival (OS) - Platinum Refractory Subgroup Based on Tumor Mutation Burden (TMB) Status [ Time Frame: Approximately up to 30 months (from FPFV to Data base lock) ]

    Overall survival was defined as the time from randomization to the date of death from any cause. Participants were censored at the date they were last known to be alive and at the date of randomization if they were randomized but had no follow-up.

    Tumor Mutational Burden (TMB) refers to the number of nonsynonymous somatic mutations that exist within a tumor's genome as measured by the Foundation One CDx panel at Foundation Medicine. The analysis was done on subjects with baseline tumor mutation burden by a cutoff of 7 mutations/megabase (mut/Mb) and 10 mut/Mb


  18. Overall Survival (OS) - Platinum Eligible Subgroup Based on HPV p-16 Status [ Time Frame: Approximately up to 30 months (from FPFV to Data base lock) ]
    Overall survival was defined as the time from randomization to the date of death from any cause. Participants were censored at the date they were last known to be alive and at the date of randomization if they were randomized but had no follow-up.

  19. Overall Survival (OS) - Platinum Eligible Subgroup Based on Tumor Mutation Burden (TMB) Status [ Time Frame: Approximately up to 30 months (from FPFV to Data base lock) ]

    Overall survival was defined as the time from randomization to the date of death from any cause. Participants were censored at the date they were last known to be alive and at the date of randomization if they were randomized but had no follow-up.

    Tumor Mutational Burden (TMB) refers to the number of nonsynonymous somatic mutations that exist within a tumor's genome as measured by the Foundation One CDx panel at Foundation Medicine. The analysis was done on subjects with baseline tumor mutation burden by a cutoff of 7 mutations/megabase (mut/Mb) and 10 mut/Mb


  20. Progression Free Survival (PFS) - Platinum Eligible Subgroup Based on Tumor Mutation Burden (TMB) Status [ Time Frame: Approximately up to 30 months (from FPFV to Data base lock) ]

    the time from randomization to the date of first documented disease progression, or death due to any cause, whichever occurs first.

    Tumor Mutational Burden (TMB) refers to the number of nonsynonymous somatic mutations that exist within a tumor's genome as measured by the Foundation One CDx panel at Foundation Medicine. The analysis was done on subjects with baseline tumor mutation burden by a cutoff of 7 mutations/megabase (mut/Mb) and 10 mut/Mb


  21. Progression Free Survival (PFS) - Platinum Eligible Subgroup Based on HPV p-16 Status [ Time Frame: Approximately up to 30 months (from FPFV to Data base lock) ]
    the time from randomization to the date of first documented disease progression, or death due to any cause, whichever occurs first.

  22. Duration of Response (DOR) - Platinum Eligible Subgroup Based on HPV p-16 Status [ Time Frame: Approximately up to 30 months (from FPFV to Data base lock) ]
    The time between the date of first confirmed response to the date of the first documented tumor progression, or death due to any cause, whichever occurs first.

  23. Duration of Response (DOR) - Platinum Eligible Subgroup Based on Tumor Mutation Burden (TMB) Status [ Time Frame: Approximately up to 30 months (from FPFV to Data base lock) ]

    The time between the date of first confirmed response to the date of the first documented tumor progression, or death due to any cause, whichever occurs first.

    Tumor Mutational Burden (TMB) refers to the number of nonsynonymous somatic mutations that exist within a tumor's genome as measured by the Foundation One CDx panel at Foundation Medicine. The analysis was done on subjects with baseline tumor mutation burden by a cutoff of 7 mutations/megabase (mut/Mb) and 10 mut/Mb


  24. Duration of Response (DOR) - Platinum Refractory Subgroup Based on PD-L1 Status [ Time Frame: Approximately up to 30 months (from FPFV to Data base lock) ]

    The time between the date of first confirmed response to the date of the first documented tumor progression, or death due to any cause, whichever occurs first.

    Tumor PD-L1 expression was defined as the percent of tumor cell membrane staining in a minimum of 100 evaluable tumor cells per validated Dako PD-L1 IHC assay


  25. ORR - Platinum Refractory Subgroup Based on PD-L1 Expression [ Time Frame: Approximately up to 30 months (from FPFV to Data base lock) ]

    ORR is defined as the best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized participants for each treatment group.

    Tumor PD-L1 expression was defined as the percent of tumor cell membrane staining in a minimum of 100 evaluable tumor cells per validated Dako PD-L1 IHC assay


  26. Overall Survival (OS) - Platinum Refractory Subgroup Based on PD-L1 Status [ Time Frame: Approximately up to 30 months (from FPFV to Data base lock) ]

    Overall survival was defined as the time from randomization to the date of death from any cause. Participants were censored at the date they were last known to be alive and at the date of randomization if they were randomized but had no follow-up.

    Tumor PD-L1 expression was defined as the percent of tumor cell membrane staining in a minimum of 100 evaluable tumor cells per validated Dako PD-L1 IHC assay


  27. Progression Free Survival (PFS) - Platinum Refractory Subgroup Based on PD-L1 Status [ Time Frame: Approximately up to 30 months (from FPFV to Data base lock) ]

    The time from randomization to the date of first documented disease progression, or death due to any cause, whichever occurs first.

    Tumor PD-L1 expression was defined as the percent of tumor cell membrane staining in a minimum of 100 evaluable tumor cells per validated Dako PD-L1 IHC assay


  28. Duration of Response (DOR) - Platinum Eligible Subgroup Based on PD-L1 Status [ Time Frame: Approximately up to 30 months (from FPFV to Data base lock) ]

    The time between the date of first confirmed response to the date of the first documented tumor progression, or death due to any cause, whichever occurs first.

    Tumor PD-L1 expression was defined as the percent of tumor cell membrane staining in a minimum of 100 evaluable tumor cells per validated Dako PD-L1 IHC assay


  29. ORR - Platinum Eligible Subgroup Based on PD-L1 Expression [ Time Frame: Approximately up to 30 months (from FPFV to Data base lock) ]

    ORR is defined as the best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized participants for each treatment group.

    Tumor PD-L1 expression was defined as the percent of tumor cell membrane staining in a minimum of 100 evaluable tumor cells per validated Dako PD-L1 IHC assay


  30. Overall Survival (OS) - Platinum Eligible Subgroup Based on PD-L1 Status [ Time Frame: Approximately up to 30 months (from FPFV to Data base lock) ]

    Overall survival was defined as the time from randomization to the date of death from any cause. Participants were censored at the date they were last known to be alive and at the date of randomization if they were randomized but had no follow-up.

    Tumor PD-L1 expression was defined as the percent of tumor cell membrane staining in a minimum of 100 evaluable tumor cells per validated Dako PD-L1 IHC assay


  31. Progression Free Survival (PFS) - Platinum Eligible Subgroup Based on PD-L1 Status [ Time Frame: Approximately up to 30 months (from FPFV to Data base lock) ]

    The time from randomization to the date of first documented disease progression, or death due to any cause, whichever occurs first.

    Tumor PD-L1 expression was defined as the percent of tumor cell membrane staining in a minimum of 100 evaluable tumor cells per validated Dako PD-L1 IHC assay




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Confirmed squamous cell head and neck cancer
  • Widespread (metastatic) disease, or returned after previous treatment (recurrent)
  • Tumor sample must be available for analysis of PDL1 (Programmed death-ligand 1) and HPV [Human Papilloma Virus (oropharynx only)]
  • Performance status ECOG 0-1 (Eastern Cooperative Oncology Group)

Exclusion Criteria:

  • Previous treatment for metastatic or recurrent disease
  • Cancer arising from one of the following primary sites: paranasal sinus, nasopharynx, salivary gland, skin
  • Any non-squamous subtype
  • Active autoimmune disease
  • Positive test for hepatitis B, C or HIV (Human Immunodeficiency Virus) virus
  • Previous treatment with checkpoint inhibitor drugs
  • Active CNS metastases or carcinomatous meningitis

Other protocol-defined inclusion/exclusion criteria apply


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02823574


Locations
Show Show 105 study locations
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Layout table for investigator information
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  Study Documents (Full-Text)

Documents provided by Bristol-Myers Squibb:
Study Protocol  [PDF] May 25, 2018
Statistical Analysis Plan  [PDF] May 30, 2018

Additional Information:
Layout table for additonal information
Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT02823574    
Other Study ID Numbers: CA209-714
2016-001645-64 ( EudraCT Number )
First Posted: July 6, 2016    Key Record Dates
Results First Posted: April 21, 2022
Last Update Posted: April 21, 2022
Last Verified: March 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Squamous Cell
Squamous Cell Carcinoma of Head and Neck
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
Head and Neck Neoplasms
Neoplasms by Site
Nivolumab
Ipilimumab
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action